Adageis, a forward-thinking healthcare technology company, has a comprehensive suite of AI-powered solutions aimed at providers shifting from fee-for-service to value-based care. With growing policy support and payer incentives, value-based care has become a pressing priority across U.S. healthcare systems. But many providers—especially smaller ones—lack the tools to navigate this transition efficiently and profitably. Adageis makes it all possible.
At the core of the company’s offering is its ProActive Care Platform, which combines predictive analytics with real-time data integration to improve both clinical and financial outcomes. The platform’s Patented Risk Engine (“PRE”) enables users to forecast revenue based on quality performance metrics and patient care patterns. For providers managing contracts that tie compensation to outcomes, these insights are increasingly important.
One area where Adageis stands out is its ability to help clients advocate for themselves with insurers. As the complexity of payer agreements grows, many providers are unsure of what they’re actually owed. Adageis uses its platform to analyze contract terms, performance metrics, and historical claims data, to tell providers what payments they should be receiving—and where they may be falling short.
This approach positions Adageis not just as a service provider, but as an advocate. By delivering insight into financial performance and payer compliance, the company enables providers to push back against underpayments and negotiate from a position of strength.
The company’s platform is already serving 70 providers and covering over 260,000 patient lives. It has been integrated with more than 90 electronic health record (“EHR”) systems, including platforms like Epic, AthenaHealth, Cerner, and eClinicalWorks. This broad interoperability is essential to the company’s strategy of scaling rapidly across provider types and geographies.
A key benefit for providers is improved cash flow predictability. By using AI to model expected payments from accountable care organizations (“ACOs”), independent physician associations (“IPAs”), clinically integrated networks (“CINs”), and insurers, Adageis helps providers better manage their revenue cycles. For some clients, this has translated into as much as $75,000 in additional annual value-based care revenue.
The company is preparing for a significant expansion by the end of Q2 2025. It anticipates reaching 580,000 covered lives, generating $100,000 in monthly recurring revenue, and onboarding two to three new clients each month. As part of this growth strategy, Adageis has reduced its implementation time to just one week, a shift that could help smaller practices adopt its technology without major operational disruption.
Looking ahead, Adageis is collaborating with investors to develop additional tools for small and independent practices. These offerings are expected to focus on lowering onboarding costs, expanding financial access, and simplifying value-based care participation for providers without in-house administrative infrastructure.
In a healthcare landscape where policy and payer structures are evolving quickly, Adageis is betting that data-driven advocacy and financial insight will become essential for survival—particularly for providers serving complex or underserved populations. For investors seeking to enter the healthcare technology space, the company’s combination of AI, finance, and operational support represents a one-of-a-kind approach within a crowded field.
For more information, visit the company’s website at www.Adageis.com.
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
A new study focusing on twins has found that individuals with a larger presence of…
Stem cells are the “master cells” within the body because they can grow into any…
UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast…
Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M…
An increase in deaths from COVID-19 underscores the persistent danger of the virus and the…
A new study whose findings appeared in the journal Heliyon has found that individuals that…